TWI618541B - Ｔｏｍｍ３４胜肽與含此胜肽之疫苗 - Google Patents

Ｔｏｍｍ３４胜肽與含此胜肽之疫苗 Download PDF

Info

Publication number
TWI618541B
TWI618541B TW100143251A TW100143251A TWI618541B TW I618541 B TWI618541 B TW I618541B TW 100143251 A TW100143251 A TW 100143251A TW 100143251 A TW100143251 A TW 100143251A TW I618541 B TWI618541 B TW I618541B
Authority
TW
Taiwan
Prior art keywords
peptide
present
item
cancer
tomm34
Prior art date
Application number
TW100143251A
Other languages
English (en)
Chinese (zh)
Other versions
TW201225973A (en
Inventor
中村祐輔
Yusuke Nakamura
角田卓也
Takuya Tsunoda
大澤龍司
Ryuji Osawa
吉村祥子
Sachiko Yoshimura
渡邊朝久
Tomohisa Watanabe
中山岳
Gaku Nakayama
Original Assignee
腫瘤療法 科學股份有限公司
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 腫瘤療法 科學股份有限公司, Oncotherapy Science, Inc. filed Critical 腫瘤療法 科學股份有限公司
Publication of TW201225973A publication Critical patent/TW201225973A/zh
Application granted granted Critical
Publication of TWI618541B publication Critical patent/TWI618541B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
TW100143251A 2010-12-02 2011-11-25 Ｔｏｍｍ３４胜肽與含此胜肽之疫苗 TWI618541B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41918110P 2010-12-02 2010-12-02
US61/419,181 2010-12-02

Publications (2)

Publication Number Publication Date
TW201225973A TW201225973A (en) 2012-07-01
TWI618541B true TWI618541B (zh) 2018-03-21

Family

ID=46171433

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100143251A TWI618541B (zh) 2010-12-02 2011-11-25 Ｔｏｍｍ３４胜肽與含此胜肽之疫苗

Country Status (23)

Country Link
US (3) US9125849B2 (enExample)
EP (1) EP2646546B1 (enExample)
JP (2) JP6064186B2 (enExample)
KR (1) KR102004900B1 (enExample)
CN (2) CN103339253B (enExample)
AR (1) AR084095A1 (enExample)
AU (1) AU2011336019B2 (enExample)
BR (1) BR112013013158B1 (enExample)
CA (1) CA2819463C (enExample)
CO (1) CO6862100A2 (enExample)
DK (1) DK2646546T3 (enExample)
EA (1) EA028216B1 (enExample)
ES (1) ES2677118T3 (enExample)
IL (1) IL226068B (enExample)
MX (1) MX344586B (enExample)
MY (1) MY166516A (enExample)
NZ (1) NZ611361A (enExample)
PH (1) PH12013501105A1 (enExample)
SG (2) SG190407A1 (enExample)
TW (1) TWI618541B (enExample)
UA (1) UA110119C2 (enExample)
WO (1) WO2012073459A1 (enExample)
ZA (1) ZA201303886B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6283861B2 (ja) 2012-09-11 2018-02-28 オンコセラピー・サイエンス株式会社 Ｕｂｅ２ｔペプチドおよびそれを含むワクチン
JP2015228191A (ja) * 2014-06-03 2015-12-17 カシオ計算機株式会社 コンテンツ出力システム、コンテンツ出力方法、コンテンツ出力プログラム、および通信端末
CN107534710B (zh) * 2016-02-29 2019-07-23 京瓷办公信息系统株式会社 电子设备以及标记处理方法
CN110191703B (zh) 2017-01-25 2022-04-08 奥塞免疫疗法公司 用于肽递送的稳定乳液的制造方法
CN117187267A (zh) * 2022-10-20 2023-12-08 福州福瑞医学检验实验室有限公司 Tomm34突变基因、检测其的引物、试剂盒和方法以及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101278196A (zh) * 2005-07-27 2008-10-01 肿瘤疗法科学股份有限公司 结肠癌相关基因tom34
TW200844111A (en) * 2007-02-21 2008-11-16 Oncotherapy Science Inc Peptide vaccines for cancers expressing tumor-associated antigens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
DE69020143T2 (de) 1989-02-17 1996-01-25 Chiron Mimotopes Pty Ltd Verfahren zur verwendung und herstellung von peptiden.
WO1994021808A1 (de) * 1993-03-19 1994-09-29 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von krebsvakzinen
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO2001049310A1 (en) 2000-01-03 2001-07-12 Argonex Pharmaceuticals, Inc. C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040181344A1 (en) 2002-01-29 2004-09-16 Massachusetts Institute Of Technology Systems and methods for providing diagnostic services
WO2003104275A2 (en) * 2002-06-06 2003-12-18 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
EP2267023B1 (en) * 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
DE602004015064D1 (de) 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
SI1620456T1 (sl) * 2003-04-18 2014-05-30 Biotech Synergy, Inc. Hla-a2 s tumorjem povezan antigen peptidov in sestavki
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
KR101744514B1 (ko) * 2009-03-18 2017-06-08 온코세라피 사이언스 가부시키가이샤 Ｎｅｉｌ3 펩티드 및 이를 포함하는 백신

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101278196A (zh) * 2005-07-27 2008-10-01 肿瘤疗法科学股份有限公司 结肠癌相关基因tom34
TW200844111A (en) * 2007-02-21 2008-11-16 Oncotherapy Science Inc Peptide vaccines for cancers expressing tumor-associated antigens

Also Published As

Publication number Publication date
SG10201509823WA (en) 2015-12-30
BR112013013158B1 (pt) 2020-04-28
US20170198010A1 (en) 2017-07-13
NZ611361A (en) 2014-10-31
AR084095A1 (es) 2013-04-17
JP2016222676A (ja) 2016-12-28
PH12013501105A1 (en) 2013-08-05
IL226068B (en) 2019-01-31
CN103339253B (zh) 2015-09-09
EP2646546B1 (en) 2018-05-16
CN103339253A (zh) 2013-10-02
AU2011336019A1 (en) 2013-07-04
KR102004900B1 (ko) 2019-07-29
MY166516A (en) 2018-07-05
DK2646546T3 (en) 2018-08-06
CA2819463C (en) 2018-10-23
CN105111281A (zh) 2015-12-02
AU2011336019B2 (en) 2016-07-07
US9125849B2 (en) 2015-09-08
BR112013013158A2 (pt) 2017-08-01
EP2646546A1 (en) 2013-10-09
TW201225973A (en) 2012-07-01
JP2014506114A (ja) 2014-03-13
US9585948B2 (en) 2017-03-07
US20140023671A1 (en) 2014-01-23
US20150374810A1 (en) 2015-12-31
CA2819463A1 (en) 2012-06-07
MX2013006014A (es) 2013-07-29
EA028216B1 (ru) 2017-10-31
CO6862100A2 (es) 2014-02-10
UA110119C2 (xx) 2015-11-25
IL226068A0 (en) 2013-06-27
EA201390811A1 (ru) 2013-12-30
WO2012073459A1 (en) 2012-06-07
ZA201303886B (en) 2014-03-26
ES2677118T3 (es) 2018-07-30
EP2646546A4 (en) 2015-12-23
KR20130121910A (ko) 2013-11-06
JP6064186B2 (ja) 2017-01-25
MX344586B (es) 2016-12-20
SG190407A1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
WO2011125334A1 (en) Cdca5 peptides and vaccines including the same
TWI485245B (zh) 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
KR102015648B1 (ko) Ｍｐｈｏｓｐｈ１ 펩티드 및 이를 포함한 백신
US20170198010A1 (en) Tomm34 peptides and vaccines including the same
US20160368958A1 (en) Hjurp peptides and vaccines including the same
TWI538685B (zh) Ｅｃｔ２胜肽及含此胜肽之疫苗
WO2012032764A1 (en) Ttll4 peptides and vaccines containing the same
WO2011074236A1 (en) Tmem22 peptides and vaccines including the same
CN103270156B (zh) Wdhd1肽及包含它们的疫苗
US20130287805A1 (en) C18orf54 peptides and vaccines including the same

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees